Advertisement
PCRX vs SNDL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a Hold and SNDL is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCRX’s FA Score shows that 1 FA rating(s) are green whileSNDL’s FA Score has 0 green FA rating(s).
- PCRX’s FA Score: 1 green, 4 red.
- SNDL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCRX’s TA Score shows that 4 TA indicator(s) are bullish while SNDL’s TA Score has 4 bullish TA indicator(s).
- PCRX’s TA Score: 4 bullish, 6 bearish.
- SNDL’s TA Score: 4 bullish, 3 bearish.
Price Growth
PCRX (@Pharmaceuticals: Generic) experienced а -1.56% price change this week, while SNDL (@Beverages: Alcoholic) price change was -5.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.63%. For the same industry, the average monthly price growth was +7.19%, and the average quarterly price growth was +30.15%.
The average weekly price growth across all stocks in the @Beverages: Alcoholic industry was -1.21%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was -30.02%.
Reported Earning Dates
PCRX is expected to report earnings on Oct 29, 2026.
SNDL is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+2.63% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Beverages: Alcoholic (-1.21% weekly)The alcoholic beverage market includes beer, wine, and spirits. From $230 billion in 2015, the industry has grown to around $250 billion by 2019. In recent years, alcoholic beverage makers have been looking to expand distribution and purchase channels, such as through online stores (e.g. e-commerce platform Drizly) and convenience stores. Anheuser-Busch In Bev and Diageo are major global alcoholic beverage companies, while U.S.-owned companies include Constellation Brands and Brown-Forman Corp. among several others.
| PCRX | SNDL | PCRX / SNDL | |
| Capitalization | 956M | 306M | 312% |
| EBITDA | 118M | 39.6M | 298% |
| Gain YTD | -7.264 | -25.904 | 28% |
| P/E Ratio | 68.54 | N/A | - |
| Revenue | 735M | 928M | 79% |
| Total Cash | 202M | 187M | 108% |
| Total Debt | 411M | 166M | 248% |
PCRX | SNDL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 91 | |
PRICE GROWTH RATING 1..100 | 60 | 74 | |
P/E GROWTH RATING 1..100 | 16 | 90 | |
SEASONALITY SCORE 1..100 | 50 | 48 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNDL's Valuation (41) in the null industry is in the same range as PCRX (65) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew similarly to PCRX’s over the last 12 months.
SNDL's Profit vs Risk Rating (100) in the null industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that SNDL’s stock grew similarly to PCRX’s over the last 12 months.
PCRX's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as SNDL (91) in the null industry. This means that PCRX’s stock grew similarly to SNDL’s over the last 12 months.
PCRX's Price Growth Rating (60) in the Pharmaceuticals Other industry is in the same range as SNDL (74) in the null industry. This means that PCRX’s stock grew similarly to SNDL’s over the last 12 months.
PCRX's P/E Growth Rating (16) in the Pharmaceuticals Other industry is significantly better than the same rating for SNDL (90) in the null industry. This means that PCRX’s stock grew significantly faster than SNDL’s over the last 12 months.
| PCRX | SNDL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| Advances ODDS (%) | 2 days ago 71% | N/A |
| Declines ODDS (%) | 6 days ago 76% | 7 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 85% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MSSIX | 22.92 | N/A | N/A |
| Victory Trivalent International Sm-Cp R6 | |||
| WCMOX | 15.23 | N/A | N/A |
| WCM Focused International Opps Ins | |||
| JGYIX | 15.01 | N/A | N/A |
| JHancock Global Shareholder Yield I | |||
| TRMNX | 25.88 | N/A | N/A |
| T. Rowe Price Mid-Cap Index | |||
| RMFCX | 64.80 | -0.05 | -0.08% |
| American Funds American Mutual R-3 | |||
PCRX and
Correlation & Price change
A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.
| Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
|---|---|---|---|---|
| PCRX | 100% | +3.27% | ||
| ELAN - PCRX | 32% Poorly correlated | +0.13% | ||
| XERS - PCRX | 29% Poorly correlated | +3.87% | ||
| COLL - PCRX | 27% Poorly correlated | +1.53% | ||
| ACET - PCRX | 27% Poorly correlated | +4.23% | ||
| SNDL - PCRX | 26% Poorly correlated | N/A | ||
More | ||||